Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma: early-phase trial registry
78 of 200 indexed Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #49 of 28,707 conditions by registered trial count.
200 US clinical trials · 78 currently recruiting · #49 of 28,707 conditions by registered trial count
Glioblastoma: 200 US clinical trials tracked, 78 recruiting.
Glioblastoma is the subject of 200 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition glioblastoma
OPEN 78 | RECR 39% | LATE 15 | EARLY 148 | RANK #49 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloid Leukemia (39% recruiting · 36 trials)
Glioblastoma lists 78 open slots (39% of 200 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma recruits in line with its size-band peers.
78 of 200 indexed trials (39%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioblastoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 10 of 200 trials (5%). 112 distinct sponsors appear on at least one study for this condition label.
-
Most Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 200 trials that report a genuine target (sentinel values excluded). 153 of those (76.5%) plan for fewer than 100 participants.
-
Glioblastoma research is mostly interventional.
186 interventional and 14 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
200 total, page 3 of 4
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis Pharmaceuticals
NCT05109728
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Patrick Wen, MD
NCT04606316
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT03718767
GammaTile and Stupp in Newly Diagnosed GBM
GT Medical Technologies
NCT05342883
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
NCT03514069
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
NCT05236036
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
Medical College of Wisconsin
NCT03297125
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
NCT03919071
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT04528680
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
NCT03491683
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
NCT03197506
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
NCT04752813
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Memorial Sloan Kettering Cancer Center
NCT04469075
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT04817254
AB154 Combined With AB122 for Recurrent Glioblastoma
Yale University
NCT04656535
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
NCT02981940
Study of Pamiparib in Newly Diagnosed and rGBM
Nader Sanai
NCT04614909
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
University of California, San Francisco
NCT03739372
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Annick Desjardins, MD
NCT03688178
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
University of Florida
NCT03405792
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
NCT04225039
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
University of Florida
NCT05353530
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT03743662
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
NCT03581292
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
Medical College of Wisconsin
NCT04747145
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
NCT03535350
Azeliragon in MGMT Unmethylated Glioblastoma
Cantex Pharmaceuticals
NCT05986851
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
NCT04221503
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
University of Michigan Rogel Cancer Center
NCT04574856
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
NCT03389230
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
University of Oklahoma
NCT03587038
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Medical College of Wisconsin
NCT04319276
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Jethro Hu
NCT03451799
Personalized Radiation Therapy for GBM
Abramson Cancer Center at Penn Medicine
NCT03477513
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT04047706
A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
University of Louisville
NCT01985087
Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue
Case Comprehensive Cancer Center
NCT04545177
A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging
Weill Medical College of Cornell University
NCT04691960
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
Bryan Allen
NCT04900792
Tofacitinib in Recurrent GBM Patients
University of Texas Southwestern Medical Center
NCT05326464
Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
West Virginia University
NCT04922723
Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors
Michigan State University
NCT01535911
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Emory University
NCT05798507
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Adilia Hormigo
NCT03223103
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
Northwell Health
NCT03630289
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
James Markert, MD
NCT06614855
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
NCT04216329
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
NCT04661384
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Immunomic Therapeutics
NCT05698199
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 61 |
| Phase 3 | 13 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma page
200 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 78 Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Glioblastoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma condition card totals 200 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.